Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram

BackgroundSorafenib, a kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC) but provides only a limited survival benefit. Disulfiram (DSF), a drug for treating alcoholism and a chelator of copper (Cu), forms a complex with Cu (DSF/Cu). DSF/Cu is a potent inducer of a...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Gong Zhang, Yufeng Wang, Bryan C. Fuchs, Wei Guo, David L. Drum, Derek J. Erstad, Baomin Shi, Albert B. DeLeo, Hui Zheng, Lei Cai, Liyuan Zhang, Kenneth K. Tanabe, Xinhui Wang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-07-01
coleção:	Frontiers in Oncology
Assuntos:	sorafenib disulfiram copper hepatic cancer stem cells ERK pathway
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2022.913736/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!